The primary objective of this study is to describe in patients with plaque psoriasis the dose level at which no dose limiting toxi cities occur following a single intravenous infusion of MEDI-507. Secondary objectives: 1) to evaluate serum concentrations of MEDI-507, 2) to evaluate the pharmacodynamic effects of MEDI-507 on the absolute lymphocyte count and the dynamics of the following lymphocyte phenotypes: CD2, CD3, CD19(+)20(+) and CD16(+)56(+) in the peripheral blood, 3) to desribe CD2 receptor occupancy by MEDI-507, 4) to describe CD2 receptor occupancy by MEDI-507, 5) to describe the change in the clinical grade and histopathology of plaque psoriasis in MEDI-507 recipients, 6) to evaluate development of anti-MEDI-507 antibodies. T-cells are an essential part of the pathophysiology of psoriasis, and agents active against T-cells have ameliorated the disease. MEDI-507, a humanized monoclonal antibody, binds to the CD2 receptor found on the surfacces of T-cells and natural killer (NK) cells and may suppress the function of these cells or eliminate them from the circulation. This open-label protocol is the first administration of MEDI-507 to psoriatic patients. It will describe safety, adverse reactions, lymphocyte population kinetics, change in psoriasis clinical grade and histopathology, specific serum cytokine concentrations, serum MEDI-507 concentrations and MEDI-507 immunogenicity.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Fourman, Lindsay T; Czerwonka, Natalia; Shaikh, Sofia D et al. (2018) Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS 32:927-932
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Foldyna, Borek; Fourman, Lindsay T; Lu, Michael T et al. (2018) Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr 78:421-428
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Srinivasa, Suman; Lu, Michael T; Fitch, Kathleen V et al. (2018) Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther 23:1-9

Showing the most recent 10 out of 945 publications